PRIME MEMBER EXCLUSIVE | 3 Months Free Trial

Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
A Call to Lead @LifeScience ORG cover art

A Call to Lead @LifeScience ORG

A Call to Lead @LifeScience ORG

Written by: LifeScience ORG
Listen for free

A Call To Lead is a series shining a light on the leadership, vision, and impact of European life science CEOs who are proving that world-class ventures don’t need to be built in Boston to shape the future of healthcare. Each episode features a one-on-one conversation with a European life science CEO and member of the LifeScience ORG community. Our conversations are not about companies or pipelines; instead, guests reflect on their personal journeys, the pivotal choices that shaped their careers, and the future they are helping to build. These kinds of insights are rarely shared publicly. New episodes are released every Thursday.Copyright LifeScience Connect Ltd Biological Sciences Economics Leadership Management & Leadership Science
Episodes
  • Susan Hill, Mestag Therapeutics
    Jun 24 2026

    Why is condensing information a critical skill for a CEO?

    How do you keep dozens of people across different functions of a company feel like one team?

    And why should you keep patients and caregivers at the centre of drug discovery?

    Today I’m joined by Susan Hill, CEO of Mestag Therapeutics, a Cambridge-based company developing new programs for cancer and inflammatory disease.

    We’ll touch on the science towards the end of the episode.

    About LifeScience ORG

    It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

    The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.

    Chapters

    0:00 – From Lab to Boardroom

    6:23 – The Call to Lead

    10:26 – Knowing When to Jump

    14:12 – Comfortable with Uncertainty

    16:33 – Shared Challenges at the Top

    21:01 – The Art of Condensing

    27:56 – Tackling Solid Tumors

    32:46 – Multiple Teams, One Mission

    34:36 – Closing the Gap for Patients

    39:00 – Sailing Toward the Horizon

    Show More Show Less
    41 mins
  • Danuta Jeziorska, Uncover Therapeutics
    Jun 18 2026

    How does a cancer diagnosis completely rewire your leadership style?

    Why is maintaining your mindset a core responsibility of a CEO?

    And what is the question every leader should ask themselves before they make a decision?

    Today I’m joined by Danuta Jeziorska, the former CEO and co-founder of Nucleome and current CEO and co-founder of Uncover Therapeutics based in Oxford. Uncover is an immuno-oncology company turning cancer’s immunoshield into an immunobeacon.

    And we’ll get more into the science of that towards the end of the episode.

    About LifeScience ORG

    It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

    The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.

    Chapters

    0:58 — Fascination With the Code of Life

    5:06 — The CV in the Suitcase

    12:54 — From the Lab to the Boardroom

    17:20 — A Pandemic, a Diagnosis and a Company to Run

    21:03 — Leading From Purpose Not Fear

    25:26 — The CEO's Most Underrated Responsibility

    30:48 — Why She Said Yes to Oncology

    32:34 — What Europe Must Do Differently

    Show More Show Less
    39 mins
  • Stefanie Flückiger, TOLREMO Therapeutics
    Jun 3 2026

    What happens when the science you built a company on becomes the science you desperately wish could save someone close?

    How do you transform as a leader as your company evolves?

    And why should you actively seek out friction when building your company?

    Today I’m joined by Stephanie Flueckiger, co-founder and CEO of TOLREMO Therapeutics based in Basel, Switzerland. TOLREMO is developing small molecules to reprogram cancer for longer patient benefit.

    As usual, we’ll talk a bit more about the science at the end of the episode.

    About LifeScience ORG

    It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

    The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.

    Chapters

    0:00 — From Science to Purpose

    1:17 — A Founder's Call to Action

    5:52 — Tragedy at the Start

    9:27 — Evolving as a Leader

    14:41 — Leading Calmly Under Pressure

    17:54 — The Swiss and European Ecosystem

    21:30 — Communicating Across Cultures

    24:42 — The Science of Drug Resistance

    29:49 — Embracing Friction

    Show More Show Less
    33 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet